BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Babiker A, Hassan M, Muhammed S, Taylor G, Poonia B, Shah A, Bagchi S. Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. Clin Cardiol 2020;43:222-34. [PMID: 31785111 DOI: 10.1002/clc.23299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Poudel KC, Poudel-Tandukar K, Bertone-Johnson ER, Pekow P, Vidrine DJ. Inflammation in Relation to Intensity and Duration of Cigarette Smoking Among People Living with HIV. AIDS Behav 2021;25:856-65. [PMID: 32986190 DOI: 10.1007/s10461-020-03048-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Szwed P, Gąsecka A, Zawadka M, Eyileten C, Postuła M, Mazurek T, Szarpak Ł, Filipiak KJ. Infections as Novel Risk Factors of Atherosclerotic Cardiovascular Diseases: Pathophysiological Links and Therapeutic Implications. J Clin Med 2021;10:2539. [PMID: 34201137 DOI: 10.3390/jcm10122539] [Reference Citation Analysis]
3 Grimm J, Peschel G, Müller M, Schacherer D, Wiest R, Weigand K, Buechler C. Rapid Decline of Serum Proprotein Convertase Subtilisin/Kexin 9 (PCSK9) in Non-Cirrhotic Patients with Chronic Hepatitis C Infection Receiving Direct-Acting Antiviral Therapy. J Clin Med 2021;10:1621. [PMID: 33920491 DOI: 10.3390/jcm10081621] [Reference Citation Analysis]
4 Jeudy J, Patel P, George N, Burrowes S, Husson J, Chua J, Conn L, Weiss RG, Bagchi S. Assessment of coronary inflammation in antiretroviral treated people with HIV infection and active HIV/hepatitis C virus co-infection. AIDS 2022;36:399-407. [PMID: 34750294 DOI: 10.1097/QAD.0000000000003125] [Reference Citation Analysis]
5 Silveira Rossi JL, Barbalho SM, Reverete de Araujo R, Bechara MD, Sloan KP, Sloan LA. Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors. Diabetes Metab Res Rev 2021;:e3502. [PMID: 34614543 DOI: 10.1002/dmrr.3502] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Babiker A, Hassan M, Muhammed S, Taylor G, Poonia B, Shah A, Bagchi S. Inflammatory and cardiovascular diseases biomarkers in chronic hepatitis C virus infection: A review. Clin Cardiol 2020;43:222-34. [PMID: 31785111 DOI: 10.1002/clc.23299] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
7 Alaarag AF, Hamam AM, Amin OA. The Safety of The Directly Acting Antiviral Treatment For Hepatitis C Virus According To The Egyptian National Program Protocol In Patients With Midrange Ejection Fraction. Glob Heart 2021;16:3. [PMID: 33598383 DOI: 10.5334/gh.906] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Roguljic H, Nincevic V, Bojanic K, Kuna L, Smolic R, Vcev A, Primorac D, Vceva A, Wu GY, Smolic M. Impact of DAA Treatment on Cardiovascular Disease Risk in Chronic HCV Infection: An Update. Front Pharmacol 2021;12:678546. [PMID: 34045969 DOI: 10.3389/fphar.2021.678546] [Reference Citation Analysis]
9 Lembas A, Zawartko K, Sapuła M, Mikuła T, Kozłowska J, Wiercińska-drapało A. VCAM-1 as a Biomarker of Endothelial Function among HIV-Infected Patients Receiving and Not Receiving Antiretroviral Therapy. Viruses 2022;14:578. [DOI: 10.3390/v14030578] [Reference Citation Analysis]
10 Neag MA, Mitre AO, Catinean A, Buzoianu AD. Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. World J Gastroenterol 2021; 27(43): 7446-7461 [PMID: 34887642 DOI: 10.3748/wjg.v27.i43.7446] [Reference Citation Analysis]